Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 04 tags : Treatment save search
Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing –
Published: 2021-06-04 (Crawled : 23:00) - biospace.com/
CMRX | $0.8844 -5.14% -5.42% 430K
|
Health Technology
|
| O: 0.24%
H: 10.33%
C: 3.21%
food treatment antiviral drug smallpox approval
Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants, One Equity Partners Open Water I Corp. Announces Receipt of NASDAQ Continued Listing Standard Notice
Published: 2021-06-04 (Crawled : 21:00) - prnewswire.com
OEPW | $10.07 -0.1% 3.18%
|
| Email alert
Add to watchlist
treatment
Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants, Marlin Technology Corporation Announces Receipt of NASDAQ Continued Listing Standard Notice
Published: 2021-06-04 (Crawled : 21:00) - prnewswire.com
FINM 4 | $10.14 0.0% 120K
|
| Email alert
Add to watchlist
treatment technology
Stemming from SEC Guidance Concerning Accounting Treatment of Warrants, Golden Arrow Merger Corp. Announces Receipt of Nasdaq Continued Listing Standard Notice
Published: 2021-06-04 (Crawled : 21:00) - globenewswire.com
GAMC | $10.63 0.0% 110
|
| Email alert
Add to watchlist
treatment merge
Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 0.38%
H: 1.25%
C: -0.76%
MOR | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 3.74%
H: 3.11%
C: 2.76%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.33%
H: 1.54%
C: 0.19%
treatment phase 2 results als
Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox
Published: 2021-06-04 (Crawled : 19:00) - globenewswire.com
CMRX | $0.8844 -5.14% -5.42% 430K
|
Health Technology
| Email alert
Add to watchlist
food treatment drug smallpox approval
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients
Published: 2021-06-04 (Crawled : 18:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.73%
H: 2.43%
C: -1.58%
treatment collaboration cancer research
A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers
Published: 2021-06-04 (Crawled : 13:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.62%
H: 3.05%
C: 1.94%
treatment blood phase 1 positive rtx-321 cancer phase 3
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
Published: 2021-06-04 (Crawled : 12:00) - 4dpharmaplc.com
LBPS | $1.65 -0.61%
|
Manufacturing
| Email alert
Add to watchlist
treatment trial enroll
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop
Published: 2021-06-04 (Crawled : 12:00) - biospace.com/
PHVS | $19.33 4.94% 4.71% 130K
|
|
| O: 1.64%
H: 1.06%
C: -1.78%
treatment ev
Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinoma
Published: 2021-06-04 (Crawled : 12:00) - globenewswire.com
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: 2.76%
H: 0.64%
C: -12.24%
treatment
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
Published: 2021-06-04 (Crawled : 12:00) - globenewswire.com
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.38%
H: 2.12%
C: 0.85%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 1.68%
H: 4.4%
C: -0.65%
treatment ongoing phase 1 phase 3
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2021-06-04 (Crawled : 01:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.04%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 7.36%
H: 1.43%
C: -5.21%
treatment therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.